Keith Chappell on a bivalent recombinant vaccine for COVID-19

from The Lancet Respiratory Medicine in conversation with · host The Lancet Group

Dr Keith Chappell discusses the bivalent recombinant vaccine for COVID-19 following the study by Dayan and colleagues, with focus on vaccine access, variants and boosters, tolerability and side effects, as well as hopes for future trials. Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

Episode metadata supplied by the publisher feed · Published Sep 13, 2023

Embed this episode

Attribution link and audio player

NOW PLAYING

Keith Chappell on a bivalent recombinant vaccine for COVID-19

0:00 8:13

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of The Lancet Respiratory Medicine in conversation with?

This episode is 8 minutes long.

When was this The Lancet Respiratory Medicine in conversation with episode published?

This episode was published on September 13, 2023.

Can I download this The Lancet Respiratory Medicine in conversation with episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!